Soligenix (SNGX) to Release Earnings on Friday

Soligenix (NASDAQ:SNGX) is anticipated to post its quarterly earnings results before the market opens on Friday, March 21st. Analysts expect Soligenix to post earnings of ($0.95) per share and revenue of $0.20 million for the quarter.

Soligenix Stock Performance

NASDAQ:SNGX opened at $2.35 on Wednesday. The stock has a fifty day moving average price of $2.42 and a two-hundred day moving average price of $3.14. The stock has a market capitalization of $5.90 million, a price-to-earnings ratio of -0.31 and a beta of 2.03. Soligenix has a 1 year low of $1.83 and a 1 year high of $14.92.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.